Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Bioorg Chem. 2020 May;98:103706. doi: 10.1016/j.bioorg.2020.103706. Epub 2020 Mar 5.
Protein tyrosine phosphatase 1B (PTP1B) is emerging as a promising yet challenging target for drug discovery. To identify natural products as new prototypes for PTP1B inhibitors, we employed a hierarchical protocol combining ligand-based and structure-based approaches for virtual screening against natural product libraries. Twenty-six compounds were prioritized for enzymatic evaluation against PTP1B, and ten of them were recognized as potent PTP1B inhibitors with IC values at the micromolar level. Notably, nine compounds demonstrated evident selectivity to PTP1B over four other PTPs, including the most homologous T-cell protein tyrosine phosphatase (TCPTP). The results implicated that the structural uniqueness of the natural products might be a potential solution to the selectivity issue associated with the target PTP1B.
蛋白酪氨酸磷酸酶 1B(PTP1B)作为一个极具前景但极具挑战性的药物研发靶点正在兴起。为了寻找天然产物作为 PTP1B 抑制剂的新原型,我们采用了一种分层方案,将基于配体和基于结构的方法相结合,对天然产物库进行虚拟筛选。有 26 种化合物被优先进行针对 PTP1B 的酶促评估,其中 10 种被认为是具有 IC50 在微摩尔级别的强效 PTP1B 抑制剂。值得注意的是,有 9 种化合物对 PTP1B 表现出明显的选择性,而对其他 4 种 PTP 则没有选择性,包括最同源的 T 细胞蛋白酪氨酸磷酸酶(TCPTP)。这些结果表明,天然产物的结构独特性可能是解决与靶标 PTP1B 相关的选择性问题的一个潜在方法。